All News

Based on phase 3 data, plinabulin plus granulocyte colony-stimulating factor is being considered by the FDA for the prevention of chemotherapy-induced neutropenia.

A 3-year follow-up analysis of event-free and overall survival revealed similar results for patients with stage II or III ERBB2-positive breast cancer treated with either neoadjuvant anthracycline and nonanthracycline treatment regimens.

Most elderly patients with acute myeloid leukemia and myelodysplastic syndromes cannot undergo intensive chemotherapy, but more than half of the patients in a new study responded to a regimen of ultra low–dose decitabine and low-dose cytarabine with G-CSF.

During an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.

A presentation at the recent 46th Annual Oncology Nursing Society’s Annual Meeting focused on ethical dilemmas facing oncology nurses and how clinicians are managing them.

Investigators successfully established the phase 2 dose of APVO436 for patients with acute myeloid leukemia or myelodysplastic syndrome after an acceptable safety profile was achieved in patients with responses to therapy.

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.

CancerNetwork® sat down with Health and Wellness expert Sonia Jhas to discuss best practices for staying active on a busy, demanding schedule.

The phase 1/2a trial reported favorable efficacy data in the first-line setting when compared with existing historical results for treating advanced pancreatic cancer.

Objective response data from a phase 2 trial supported the FDA’s decision to grant infigratinib accelerated approval to treat patients with certain a certain type of cholangiocarcinoma.

Two posters on the efficacy of trilaciclib for treating myelosuppression were presented at the Virtual International Society for Pharmacoeconomics and Outcomes Research 2021.

Based on data from the phase 1/2 CodeBreaK 100 trial, the FDA approved the KRAS G12C inhibitor sotorasib.

A phase 2 trial evaluated the combination of vemurafenib plus rituximab, which produced a complete response in 87% of the evaluable patients with hairy-cell leukemia.

CancerNetwork® spoke with Albert H. Kim, MD, PhD, about a new Brain Tumor Center at Siteman, for which he is the inaugural director.

Based on data from the CARTITUDE-1, the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel moves forward towards regulatory approval in multiple myeloma.

The approval of 18F-DCFPyL comes on the heels of positive results from the company-sponsored research in the CONDOR and OSPREY trials investigating the imaging agent for prostate cancer.

The ready-to-use subcutaneous formulation of leuprolide mesylate, Camcevi, was approved for use in patients with prostate cancer by the FDA.

Investigators aimed to determine if oncologic outcomes of patients in the real-world setting matched those of a pivotal clinical trial that led to the approval of eribulin mesylate in patients with metastatic breast cancer.

The 2020 Trending Now in Cancer report highlighted a shift in oncology care resulting from the COVID-19 pandemic.

Based on phase 3 data supporting the use of ublituximab in combination with umbralisib versus an existing standard-of-care regimen for chronic lymphocytic leukemia and small cell lymphoma, the FDA has moved forward with a review of the application for approval.

The radioimmunotherapy 177-Lu lilotomab satetraxetan in combination with rituximab led to a 100% response rate in a small cohort of patients with follicular lymphoma who were receiving treatment in the second-line setting.

Recently announced phase 3 data show similar progression-free survival results between melflufen and pomalidomide, the most used medicine for patients with relapsed or refractory multiple myeloma.

An affinity-tuned CAR T-cell product will be evaluated in thyroid cancer with a fast track designation from the FDA.

A RAF/MEK plus FAK inhibitor combination will be given an expedited review by the FDA as therapy for patients with recurrent low-grade serous ovarian cancer.

Promising results from a phase 1b trial of cabozantinib in combination with atezolizumab for patients with high-risk, locally advanced or metastatic castration-resistant prostate cancer are expected to lead to regulatory submission.

CancerNetwork®’s podcast dives into an article focused on treatment options for older, transplant-ineligible patients with multiple myeloma.

Look back at some of the important news and notes from last week you might have missed in the world of oncology. The FDA granted priority review to zanubrutinib, while 2 features from the journal ONCOLOGY® published on belantamab mafodotin and renal cell carcinoma, respectively, were popular with readers.

Phase 2 data supporting the use of loncastuximab tesirine in patients with diffuse large B-cell lymphoma published in The Lancet Oncology show the agent inducing a response in about half of patients with pretreated disease.

Penpulimab may be a future treatment option for patients with nasopharyngeal cancer in the third line of therapy dependent on success of a recent biologics license application submitted to the FDA.

Solid nodules, peritumoral interstitial thickening, and pleural contact can play a role in carefully selecting optimal patients to undergo sublobar resection instead of more extensive surgery.